ARCHIVES

In Brief: Rhoads, Schmidt Bow Out – Amos, Krim Possible Replacements; Sibal acting Virology Director

This article is from The Cancer Letter archive.

Vol. 04 No. 04 | January 27, 1978

Download PDF Visit The Full Archive

Related Articles

DT Board Oks RFAs In Surgery, HIV, Breast Cancer

June 18, 1993

Amgen’s Aranesp Sales Dropped By Half, Continue To Fall.

November 14, 2008

Cancer, AIDS Drug Screening Contracts Ok’d For Recompetition

February 28, 1992

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

October 31, 2014

In Brief: Lawyers Halt Reference Chemical Distribution To Grantees, Threaten To Stop Viruses, Animals

September 2, 1977

New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB.

October 8, 2004